Cargando…
The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial
Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a D-amino acid oxidase (DAAO) inhibitor that increases the glutamate co-agonist D-serine levels, is being developed for the treatment of cogni...
Autores principales: | O’Donnell, Patricio, Dong, Cheng, Murthy, Venkatesha, Asgharnejad, Mahnaz, Du, Xiaoming, Summerfelt, Ann, Lu, Hong, Xu, Lin, Wendland, Jens R., Dunayevich, Eduardo, Buhl, Derek L., Litman, Robert, Hetrick, William P., Hong, L. Elliot, Rosen, Laura B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018616/ https://www.ncbi.nlm.nih.gov/pubmed/36928351 http://dx.doi.org/10.1038/s41386-023-01560-0 |
Ejemplares similares
-
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers
por: Dijkstra, Francis, et al.
Publicado: (2022) -
Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
por: Fradley, Rosa, et al.
Publicado: (2023) -
Correction to: Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
por: Fradley, Rosa, et al.
Publicado: (2023) -
Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia
por: Wang, Hao, et al.
Publicado: (2021) -
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation
por: O’Donnell, Patricio, et al.
Publicado: (2021)